El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

CondeE.pdf (2.73 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2010-08-17

Llicència de publicació

cc by (c) Conde et al., 2010
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126804

The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1371/journal.pone.0012209

Resum

Introduction: While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of "carcinoma NOS (not otherwise specified)'' in a prospective series of small tumor samples. Methods: With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of 66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC. Results: The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when compared to ACs (p<0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all P63 positive cases (34%) were diagnosed as SCCs. Conclusions: P63 IHC is useful for the identification of lung SCCs.

Matèries

Càncer de pulmó, Immunohistoquímica

Matèries (anglès)

Lung cancer, Immunohistochemistry

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

CONDE, Esther, ANGULO, Bárbara, REDONDO, Pilar, TOLDOS, Oscar, GARCÍA GARCÍA, Elena, SUÁREZ GAUTHIER, Ana, RUBIO VIQUEIRA, Belén, MARRÓN, Carmen, GARCÍA LUJÁN, Ricardo, SÁNCHEZ CÉSPEDES, Montserrat, LÓPEZ ENCUENTRA, Agel, PAZ-ARES, Luis, LÓPEZ RÍOS, Fernando. The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung. _PLoS One_. 2010. Vol. 5, núm. 8, pàgs. e12209. [consulta: 8 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/126804]

Exportar metadades

JSON - METS

Compartir registre